|
Gender (female)
|
85.1%
|
|
Age (mean, years ± SD)
|
46.7 ± 12.6
|
|
Aura
|
28.6%
|
|
Migraine duration (mean, years ± SD)
|
28.6 ± 15.0
|
|
Chronification time (mean, years ± SD)
|
10.5 ± 9.9
|
|
Headache frequency (days/month ± SD)
|
26.5 ± 5.2
|
|
Moderate-Severe headache frequency (days/month ± SD)
|
12.7 ± 7.5
|
|
Moderate-Severe headache monthly rate (% ± SD)
|
49.0 ± 27.6
|
|
Acute treatment (% of use)
|
95.7%
|
|
NSAIDs
|
54.6%
|
|
Triptans
|
46.1%
|
|
Other analgesics
|
36.3%
|
|
Analgesic use (mean, tablets/month ± SD)
|
42.2 ± 42.4
|
|
Daily use of analgesic
|
38.7%
|
|
Medication overuse
|
61.3%
|
|
Stable concomitant preventive treatment (%)
|
77.0%
|
|
Neuromodulators
|
39.2%
|
|
Betablockers
|
14.9%
|
|
Antidepressants
|
61.5%
|
|
Others
|
10.6%
|
|
MIDAS disability category
|
|
None
|
5.6%
|
|
Mild
|
4.8%
|
|
Moderate
|
6.8%
|
|
Severe
|
82.8%
|
|
MIDAS score (mean ± SD)
|
82.6 ± 64.6
|
